Company news
Imugene Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Final HER-Vaxx Phase 2 Trial Overall Survival Results
June 26, 2022
Imugene doses first patient in VAXINIA Phase 1 trial
May 17, 2022
IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
May 9, 2022
Clarification Announcement
May 3, 2022
Termination of Supply Agreement
May 2, 2022
Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
March 23, 2022
Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
March 22, 2022
Imugene HER-Vaxx Clinical Trial Collaboration with Merck
March 14, 2022
Oncolytic Virotherapy CF33 Patent Granted in Japan
January 30, 2022
PD1-Vaxx Clinical Trial Supply Agreement with Roche
January 28, 2022
HER-Vaxx Immunotherapy Patent Granted in Europe
January 27, 2022
Imugene Receives $6.54 million R&D Tax Incentive
January 6, 2022
South Korea HERVaxx Patent Grant
January 5, 2022
Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx
January 3, 2022
FDA IND approval for the phase 2 clinical trial of HER-Vaxx
December 12, 2021
Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc
December 6, 2021
S&P DJI Announces December 2021 Quarterly Rebalance
December 3, 2021
Clinical Trial Supply Agreement with Merck KGaA and Pfizer
November 15, 2021
Investor Presentation Imugene Eureka Therapeutics
October 31, 2021
First patient dosed in Phase I clinical trial of CHECKvacc
October 20, 2021
Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
September 21, 2021
S&P DJI Announces September 2021 Quarterly Rebalance
September 3, 2021
Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials
August 31, 2021
Appendix 4E and Full Year Statutory Accounts
August 30, 2021
Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx
August 26, 2021
Response to ASX Query
August 23, 2021
Research partnership with Celularity for solid tumors
August 4, 2021
Prospectus for SPP and Placement Options Offer
July 29, 2021
Imugene completes $90 M placement and launches $5 M SPP
July 28, 2021
Appendix 4C - Quarterly Report
July 23, 2021
FDA IND approval of new oncolytic virotherapy CHECKvacc
July 1, 2021
Investor Presentation
May 17, 2021
Prestigious Research Journal Publish HER-Vaxx Phase 1B Data
April 29, 2021
Appendix 4C - quarterly
April 23, 2021
Imugene announces clinical milestone for HER-Vaxx
April 20, 2021
Imugene Oncolytic Virus Presentation at AACR 2021 Meeting
April 11, 2021
Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX
April 6, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting
March 10, 2021
Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial
February 11, 2021
Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial
January 20, 2021
Imugene completes recruitment to HER-Vaxx Phase 2 trialim
January 6, 2021
Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
December 16, 2020
Imugene Receives $4.82 million R&D Tax Incentive
December 10, 2020
Imugene First Patient Dosed in PD1-VAXX Clinical Trial
November 30, 2020
Imugene HER Vaxx shows positive Overall Survival in trial
November 22, 2020
Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
November 1, 2020
Imugene Immunotherapy Combination Patent Granted in US
October 1, 2020
Imugene Secures $5.7 million Option Underwriting Agreement
September 8, 2020
Imugene Receives PD1-VAXX Ethics Trial Approval in USA
September 3, 2020
Decks
The 5 newest of 54 decks. Every deck is listed under its year.
- Investor Presentation (July 2026)
Investor deck · 29 slides · Jul 7, 2026
- Investor Presentation (March 2026)
Investor deck · 31 slides · Mar 11, 2026
- Technical Presentation (February 2026)
Technical · 15 slides · February 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 16 slides · Nov 13, 2025
- Shareholder Meeting (August 2025)
Shareholder meeting · 6 slides · Aug 20, 2025